In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25. For those who self-pay, Zepbound is available starting at $349 per month on LillyDirect.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- ‘Don’t Fall for the Hype,’ Says Top Analyst about HIMS’ Decision to Sell Zepbound
- BofA says Hims & Hers Zepbound sales will be ‘immaterial’
- Hims & Hers adding access to generic liraglutide, branded tirzepatide
- Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reports
- Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports